CL2013003282A1 - Composicion farmaceutica que comprende celulas tumorales que son apoptoticas a causa de tratamiento con presion hidrostatica y celulas dendriticas; metodo de preparacion; y su uso para tratar cancer. - Google Patents

Composicion farmaceutica que comprende celulas tumorales que son apoptoticas a causa de tratamiento con presion hidrostatica y celulas dendriticas; metodo de preparacion; y su uso para tratar cancer.

Info

Publication number
CL2013003282A1
CL2013003282A1 CL2013003282A CL2013003282A CL2013003282A1 CL 2013003282 A1 CL2013003282 A1 CL 2013003282A1 CL 2013003282 A CL2013003282 A CL 2013003282A CL 2013003282 A CL2013003282 A CL 2013003282A CL 2013003282 A1 CL2013003282 A1 CL 2013003282A1
Authority
CL
Chile
Prior art keywords
apoptotic
preparation
treatment
pharmaceutical composition
hydrostatic pressure
Prior art date
Application number
CL2013003282A
Other languages
English (en)
Spanish (es)
Inventor
Jirina Bartunkova
Radek Spisek
Original Assignee
Sotio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11172622A external-priority patent/EP2543386A1/en
Application filed by Sotio As filed Critical Sotio As
Publication of CL2013003282A1 publication Critical patent/CL2013003282A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2013003282A 2011-07-05 2013-11-14 Composicion farmaceutica que comprende celulas tumorales que son apoptoticas a causa de tratamiento con presion hidrostatica y celulas dendriticas; metodo de preparacion; y su uso para tratar cancer. CL2013003282A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161504387P 2011-07-05 2011-07-05
EP11172622A EP2543386A1 (en) 2011-07-05 2011-07-05 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure

Publications (1)

Publication Number Publication Date
CL2013003282A1 true CL2013003282A1 (es) 2014-10-10

Family

ID=50023029

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003282A CL2013003282A1 (es) 2011-07-05 2013-11-14 Composicion farmaceutica que comprende celulas tumorales que son apoptoticas a causa de tratamiento con presion hidrostatica y celulas dendriticas; metodo de preparacion; y su uso para tratar cancer.

Country Status (7)

Country Link
JP (1) JP6235085B2 (hr)
CL (1) CL2013003282A1 (hr)
CY (1) CY1115803T1 (hr)
HR (1) HRP20141230T1 (hr)
IL (2) IL229702A (hr)
MX (1) MX2013013243A (hr)
ZA (1) ZA201307886B (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047507T2 (hu) 2011-10-17 2020-04-28 Massachusetts Inst Technology Intracelluláris célbajuttatás
KR102304167B1 (ko) 2013-08-16 2021-09-24 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
CA2964392A1 (en) 2014-10-31 2016-05-06 Massachussetts Institute Of Technology Delivery of biomolecules to immune cells
CN107002089B (zh) 2014-11-14 2021-09-07 麻省理工学院 化合物和组合物向细胞中的破坏和场实现的递送
EP3245294A4 (en) 2015-01-12 2018-05-30 Massachusetts Institute of Technology Gene editing through microfluidic delivery
CN107922911A (zh) 2015-07-09 2018-04-17 麻省理工学院 将物质递送至无核细胞

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases

Also Published As

Publication number Publication date
IL229702A0 (en) 2014-01-30
HRP20141230T1 (hr) 2015-02-13
JP2017025066A (ja) 2017-02-02
IL229702A (en) 2016-09-29
ZA201307886B (en) 2015-03-25
MX2013013243A (es) 2014-05-30
IL247781B (en) 2019-11-28
IL247781A0 (en) 2016-11-30
CY1115803T1 (el) 2017-01-25
JP6235085B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
CL2013003282A1 (es) Composicion farmaceutica que comprende celulas tumorales que son apoptoticas a causa de tratamiento con presion hidrostatica y celulas dendriticas; metodo de preparacion; y su uso para tratar cancer.
UA111738C2 (uk) Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітин
AR106582A1 (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
MX2018001842A (es) Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso.
CL2015001983A1 (es) Modulador del receptor de andrógeno y usos de este.
NI201200120A (es) Derivados de fumarato de ácido graso y sus usos.
BR112015008447A2 (pt) métodos para tratar câncer
ECSP13012534A (es) Composición farmacéutica
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
CL2012003209A1 (es) Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
CL2017001008A1 (es) Uso de una composicion de vacuna de hpv para tratar cancer y lesion de la piel.
PE20161133A1 (es) Filtros para equipos de infusion